fda compounding semaglutide warning letters november 2025 issued 25 to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of FDA warns against compounded GLP-1

How PlexusDx Determines Your GLP-1 Eligibility PlexusDx begins with a detailed medical questionnaire and review of your health history to establish a baseline understanding of your metabolic status

Glossary Triple Agonist A compound that simultaneously activates three distinct receptor types

A landmark 2023 study published in JCI Insight found that semaglutide significantly reduced alcohol intake in rodent models, including models of binge-like drinking

And we are going to discuss assessment and testing in great detail in Part 2

The FDA's Category 2 designation means the substance may present significant safety risks when used in compounding and is prohibited in compounded medications pending further evaluation

Zhang M, Lin S, Wang MF, Huang JF, Liu SY, Wu SM, Zhang HY, Wu ZM, Liu WY, Zhang DC, Hao CM, Zhu YY, Zheng MH, Wang XZ